Comparing Sophiris Bio (SPHS) & Mylan N.V. (MYL)
Mylan N.V. (NASDAQ: MYL) and Sophiris Bio (NASDAQ:SPHS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitabiliy, dividends, analyst recommendations, valuation, institutional ownership and risk.
This is a summary of recent ratings and price targets for Mylan N.V. and Sophiris Bio, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mylan N.V. currently has a consensus target price of $51.28, suggesting a potential upside of 36.20%. Sophiris Bio has a consensus target price of $6.60, suggesting a potential upside of 212.80%. Given Sophiris Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Sophiris Bio is more favorable than Mylan N.V..
Volatility & Risk
Mylan N.V. has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Sophiris Bio has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.
Earnings & Valuation
This table compares Mylan N.V. and Sophiris Bio’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Mylan N.V.||$11.61 billion||1.74||$3.80 billion||$1.00||37.65|
|Sophiris Bio||N/A||N/A||-$10.78 million||($0.49)||-4.31|
Mylan N.V. has higher revenue and earnings than Sophiris Bio. Sophiris Bio is trading at a lower price-to-earnings ratio than Mylan N.V., indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
69.9% of Mylan N.V. shares are owned by institutional investors. Comparatively, 6.1% of Sophiris Bio shares are owned by institutional investors. 0.7% of Mylan N.V. shares are owned by company insiders. Comparatively, 3.9% of Sophiris Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Mylan N.V. and Sophiris Bio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Mylan N.V. beats Sophiris Bio on 9 of the 13 factors compared between the two stocks.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.
About Sophiris Bio
Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.